Management of cisplatin-associated toxicities in bladder cancer patients
- 23 July 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Supportive & Palliative Care
- Vol. 14 (3) , 286-292
Abstract
Purpose of review: Cisplatin remains the treatment cornerstone for bladder cancer, either in neoadjuvant or in metastatic (cisplatin-gemcitabine or dose-dense methotrexate, vinblastine, and doxorubicin). Timely and adequate management of cisplatin's adverse events is important in order to avoid dose reductions, treatment delays, or cessation. Over the last years, several randomized studies and updated guidelines have been published on this subject.Recent findings: The incidence, physiopathology, risk factors, preventive treatment, and optimal management of such complications will be presented, with special focus on cisplatin-associated nausea and vomiting, acute kidney injury (AKI), hypomagnesemia, neurotoxicity, and ototoxicity.Summary: Optimal prevention of cisplatin-associated nausea and vomiting requires an aggressive approach with the use of a four-drug prophylactic regimen (NK1 receptor antagonist, 5-HT3 receptor antagonist, dexamethasone, olanzapine). The use of intensive hydration before and after cisplatin infusion has been the mainstay of AKI prevention. The management of hypomagnesemia and neurotoxicity remains largely symptomatic. In an adult population, no therapy has yet demonstrated benefits in the prevention or treatment of platinum-related ototoxicity.Keywords
This publication has 57 references indexed in Scilit:
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986Journal of Clinical Oncology, 2012
- Mechanisms of Cisplatin NephrotoxicityToxins, 2010
- Long‐term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancerCancer, 2010
- Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patientsThe Pharmacogenomics Journal, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional studyJournal of Translational Medicine, 2007
- Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathyCancer, 2007
- Cisplatin Nephrotoxicity: A ReviewThe American Journal of the Medical Sciences, 2007
- A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group studySupportive Care in Cancer, 2007
- Predicting cisplatin ototoxicity in children: the influence of age and the cumulative doseEuropean Journal of Cancer, 2004